Journal article
Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).
Abstract
BACKGROUND: The purpose of the study was to assess the safety, tolerability, recommended phase II dose (RPTD), and preliminary antitumor activity of the combination of carboplatin-paclitaxel (Taxol)-temsirolimus. MATERIALS AND METHODS: Patients with solid malignancies suitable for carboplatin-paclitaxel (CP) chemotherapy and two or less prior lines of chemotherapy received 15, 20, or 25 mg of temsirolimus per week with CP given every 21 days. …
Authors
Kollmannsberger C; Hirte H; Siu LL; Mazurka J; Chi K; Elit L; Walsh W; Sederias J; Doyle A; Eisenhauer EA
Journal
Ann Oncol, Vol. 23, No. 1, pp. 238–244
Publication Date
January 2012
DOI
10.1093/annonc/mdr063